{"entity":{"id":"nct06465563","kind":"trial","name":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","aka":[],"tldr":"A phase 2 trial of SHR-8068, Adebrelimab, Cisplatin, Gemcitabine and Bevacizumab in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.","summary":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT06465563 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 93 participants enrolled, started 2024-07-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: SHR-8068, Adebrelimab, Cisplatin, Gemcitabine and Bevacizumab Injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06465563","url":"https://clinicaltrials.gov/study/NCT06465563"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["shr-8068","adebrelimab","cisplatin","gemcitabine","bevacizumab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06465563","phase":"2","setting":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy for the First-Line Treatment of Advanced Biliary Tract Cancer: A Randomized and Exploratory Cohort, Open-label, Multicenter, Phase II Study","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","started":"2024-07-01","startedType":"actual","enrolled":93,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06465563/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}